The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific, Medtronic and J&J are moving quickly to secure their place in the fast-growing pulsed field ablation space ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.